-- BriaCell Therapeutics (BCT.TO) 周四宣布，已将纽约大学朗格尼医学中心 (NYU Langone Health) 的劳拉和艾萨克·珀尔穆特癌症中心 (Laura and Isaac Perlmutter Cancer Center) 纳入其正在进行的 III 期临床试验的临床试验点。 这项针对晚期乳腺癌的 III 期临床试验 (Bria-ABC) 正在评估该公司的主要候选药物 Bria-IMT 联合免疫检查点抑制剂治疗晚期转移性乳腺癌的疗效。 该 III 期临床试验将在发生 144 例患者事件（死亡）后进行中期分析，主要终点为总生存期 (OS)。 Bria-IMT 联合疗法已获得美国食品药品监督管理局 (FDA) 的快速通道资格认定。 BriaCell 股票在美国盘前交易中上涨 0.033 美元，至 4.183 美元。
Related Articles
Australia
Max Resource Applies for OTCQB Listing; Shares Down 8.2%
Max Resource (MAX.V) on Thursday said it applied to list its shares on the U.S. OTCQB market.The company's shares will continue to trade on the Toronto Stock Exchange Venture under it current symbol, it said.The company's OTCQB application is subject to OTC Markets' review and approval.The company's shares are eligible for settlement through the Depository Trust Company (DTC), which facilitates the electronic clearing and settlement of publicly traded companies in the United States, the company added."We believe that uplisting on the OTCQB would expand Max's exposure to U.S. investors, increase trading accessibility and liquidity, and support the company's efforts to build a broader international shareholder base as the exploration season advances into full swing," said chief executive Brett Matich.The company's shares were last seen down $0.025 at $0.28 on the TSX Venture Exchange.Price: $0.28, Change: $-0.03, Percent Change: -8.20%
$MAX.V
Australia
Macquarie Downgrades PayPal to Neutral From Outperform, Price Target is $50
PayPal (PYPL) has an average rating of hold and mean price target of $50.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $46.94, Change: $+0.68, Percent Change: +1.46%
$PYPL
Australia
Fortinet Set for Faster Growth on Cyber Risk, AI Upgrades, Wedbush Says
Fortinet (FTNT) is positioned for stronger growth as AI-driven infrastructure needs, rising cyber risks, product upgrades, vendor consolidation, and improving sales momentum support its revenue and billings outlook, Wedbush Securities said Thursday in a report.Q1 billings rose 31% to $2.09 billion, above Wall Street estimates, with strength across security operations and operational technology security, the report said. Revenue climbed 20%, helped by large customers upgrading to higher-performance systems for AI-related workloads, Wedbush said.Operating margins and earnings per share both exceeded expectations on strong execution and cost control, Wedbush said. Fortinet raised its 2026 revenue and billings outlook as cyber threats, data security needs, and cost pressures push customers toward broader cyber platforms, the report said.Wedbush raised its price target on Fortinet stock to $125 from $90 and maintained its outperform rating, citing greater confidence in the company's growth recovery.Price: $110.88, Change: $+20.93, Percent Change: +23.27%
$FTNT